                         SEQUENCE LISTING

<110>  F. Hoffmann-La Roche AG
 
<120>   ANTI-BRDU ANTIBODIES AND METHODS OF USE

<130>  P32181-WO

<150>  EP14174043.1
<151>  2014-06-26

<160>  14    

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  Mus musculus

<400>  1

Glu Tyr Pro Ile His 
1               5   


<210>  2
<211>  10
<212>  PRT
<213>  Mus musculus

<400>  2

Gly Tyr Thr Phe Pro Glu Tyr Pro Ile His 
1               5                   10  


<210>  3
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  humanized CDR-H2

<400>  3

Gly Ile Val Pro Asn Asn Gly Phe Thr Phe Tyr Ala Gln Lys Leu Gln 
1               5                   10                  15      


Gly 
    


<210>  4
<211>  6
<212>  PRT
<213>  Mus musculus

<400>  4

Val Pro Asn Asn Gly Phe 
1               5       


<210>  5
<211>  10
<212>  PRT
<213>  Mus musculus

<400>  5

Lys Asn Leu Gly Ser Ser Pro Leu Asp Tyr 
1               5                   10  


<210>  6
<211>  11
<212>  PRT
<213>  Mus musculus

<400>  6

Arg Ala Ser Gln Ser Ile Gly Thr Ser Ile His 
1               5                   10      


<210>  7
<211>  7
<212>  PRT
<213>  Mus musculus

<400>  7

Tyr Ala Ser Glu Ser Ile Ser 
1               5           


<210>  8
<211>  9
<212>  PRT
<213>  Mus musculus

<400>  8

Gln Gln Ser Asn Arg Trp Pro Leu Thr 
1               5                   


<210>  9
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  humanized heavy chain variable domain

<400>  9

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Pro Glu Tyr 
            20                  25                  30          


Pro Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Ile Val Pro Asn Asn Gly Phe Thr Phe Tyr Ala Gln Lys Leu 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Asn Leu Gly Ser Ser Pro Leu Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Thr Val Thr Val Ser Ser 
        115                 


<210>  10
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  humanized light chain variable domain

<400>  10

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Ser 
            20                  25                  30          


Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Asn Arg Trp Pro Leu 
                85                  90                  95      


Thr Leu Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  11
<211>  119
<212>  PRT
<213>  Mus musculus

<400>  11

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Pro Glu Tyr 
            20                  25                  30          


Pro Ile His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Gly Ile Val Pro Asn Asn Gly Phe Thr Phe Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Ser Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Val Glu Val Arg Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Asn Leu Gly Ser Ser Pro Leu Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Thr Leu Thr Val Ser Ser 
        115                 


<210>  12
<211>  107
<212>  PRT
<213>  Mus musculus

<400>  12

Asp Ile Leu Leu Thr Gln Ser Pro Ala Ile Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Ser 
            20                  25                  30          


Ile His Trp Tyr Gln His Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile 
        35                  40                  45              


Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser 
65                  70                  75                  80  


Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Ser Asn Arg Trp Pro Leu 
                85                  90                  95      


Thr Leu Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105         


<210>  13
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDR-H2 variant with Cystein at position 52b/53 according to Kabat

<400>  13

Gly Ile Val Pro Cys Asn Gly Phe Thr Phe Tyr Ala Gln Lys Leu Gln 
1               5                   10                  15      


Gly 
    


<210>  14
<211>  51
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  BRDU-DNA conjugate


<220>
<221>  misc_RNA
<222>  (1)..(1)
<223>  BRDU

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  n is a, c, g, or t

<400>  14
naccaagcct agagaggagc aatacaacag tacatatcgc gtggtaagcg t                51


